Himisha Beltran, MD

Himisha Beltran, MD

Medical Oncology

Contact Information

Office Phone Number

617-632-2429

Appointments

617-632-2682 (new)
617-582-9725 (established)

Biography

Himisha Beltran, MD

Dr. Beltran is an Associate Professor of Medicine in the Lank Center for Genitourinary Oncology and the Division of Molecular and Cellular Oncology. She is also the Director of Translational Research within Medical Oncology.

Researcher

Physician

Physician
Associate Professor of Medicine, Harvard Medical School

Centers/Programs

Clinical Interests

Precision medicine, Prostate cancer

Diseases Treated

Board Certification

  • Hematology, 2011
  • Medical Oncology, 2011

Fellowship

  • Weill Cornell Medical College

Residency

  • University of Pennsylvania

Medical School

  • New York Medical College

Recent Awards

  • American Society of Clinical Investigation (ASCI) Young Physician-Scientist Award, 2017
  • Alliance for Clinical Trials in Oncology Scholar Awards in Honor of Dr. Emil “Tom” Frei III , 2014
  • Damon Runyon Cancer Research Foundation Clinical Investigator Award, 2013
  • Prostate Cancer Foundation Young Investigator Award, 2010

Research

    The Beltran lab is focused on understanding mechanisms of treatment resistance in prostate cancer including lineage plasticity and the development of neuroendocrine prostate cancer
    My lab is focused on understanding mechanisms of treatment resistance in advanced prostate cancer through the integration of clinical and molecular features of patients combined with preclinical modeling. We have focused on understanding mechanisms underlying an emerging subclass of androgen-indifferent prostate cancers that develop neuroendocrine features as an adaptive response mechanism upon selective therapeutic pressure of the androgen receptor (AR). We have used genomics and epigenomics to elucidate the molecular mechanisms driving evolution towards an AR-low state. We are developing tissue and circulating biomarkers and novel therapeutic strategies for clinical translation. Our mission is to make discoveries that improve the way we manage and treat patients with advanced prostate cancer.
    In addition, within Dana Farber and through national and international collaborations, we work with a multidisciplinary team of scientists and clinicians towards the development of next generation molecular platforms and biomarkers for the clinical application of precision medicine across tumor types.

    Publications

      • Large Cell Neuroendocrine Prostate Cancer: Large Is Not Small. Oncologist. 2024 Jan 11. View in: Pubmed

      • Non-invasive detection of neuroendocrine prostate cancer through targeted cell-free DNA methylation. Cancer Discov. 2024 Jan 10. View in: Pubmed

      • Molecular features of prostate cancer after neoadjuvant therapy in the phase 3 CALGB 90203 trial. J Natl Cancer Inst. 2024 Jan 10; 116(1):115-126. View in: Pubmed

      • G-protein signaling of oxytocin receptor as a potential target for cabazitaxel-resistant prostate cancer. PNAS Nexus. 2024 Jan; 3(1):pgae002. View in: Pubmed

      • Prostate-Specific Membrane Antigen-Targeted Therapies for Prostate Cancer: Towards Improving Therapeutic Outcomes. Eur Urol. 2023 Dec 15. View in: Pubmed

      • Metabolically regulated lineages in prostate cancer. Nat Cell Biol. 2023 Dec; 25(12):1726-1728. View in: Pubmed

      • Targeting DNA methylation and B7-H3 in RB1-deficient and neuroendocrine prostate cancer. Sci Transl Med. 2023 Nov 15; 15(722):eadf6732. View in: Pubmed

      • Author Correction: Evolution of structural rearrangements in prostate cancer intracranial metastases. NPJ Precis Oncol. 2023 Nov 02; 7(1):113. View in: Pubmed

      • Evolution of structural rearrangements in prostate cancer intracranial metastases. NPJ Precis Oncol. 2023 Sep 13; 7(1):91. View in: Pubmed

      • The Transcriptional and Epigenetic Landscape of Cancer Cell Lineage Plasticity. Cancer Discov. 2023 08 04; 13(8):1771-1788. View in: Pubmed

      • The Identification of CELSR3 and Other Potential Cell Surface Targets in Neuroendocrine Prostate Cancer. Cancer Res Commun. 2023 08; 3(8):1447-1459. View in: Pubmed

      • Immunogenomic Landscape of Neuroendocrine Prostate Cancer. Clin Cancer Res. 2023 08 01; 29(15):2933-2943. View in: Pubmed

      • Chemokine receptor CXCR7 activates Aurora Kinase A and promotes neuroendocrine prostate cancer growth. J Clin Invest. 2023 08 01; 133(15). View in: Pubmed

      • Fragmentomic analysis of circulating tumor DNA-targeted cancer panels. Ann Oncol. 2023 09; 34(9):813-825. View in: Pubmed

      • Significance of RB Loss in Unlocking Phenotypic Plasticity in Advanced Cancers. Mol Cancer Res. 2023 06 01; 21(6):497-510. View in: Pubmed

      • Landscape of prostate-specific membrane antigen heterogeneity and regulation in AR-positive and AR-negative metastatic prostate cancer. Nat Cancer. 2023 05; 4(5):699-715. View in: Pubmed

      • Randomized Phase III Study of Enzalutamide Compared With Enzalutamide Plus Abiraterone for Metastatic Castration-Resistant Prostate Cancer (Alliance A031201 Trial). J Clin Oncol. 2023 06 20; 41(18):3352-3362. View in: Pubmed

      • Management of patients with advanced prostate cancer-metastatic and/or castration-resistant prostate cancer: Report of the Advanced Prostate Cancer Consensus Conference (APCCC) 2022. Eur J Cancer. 2023 05; 185:178-215. View in: Pubmed

      • Impact of early detection on cancer curability: A modified Delphi panel study. PLoS One. 2022; 17(12):e0279227. View in: Pubmed

      • Management of Patients with Advanced Prostate Cancer. Part I: Intermediate-/High-risk and Locally Advanced Disease, Biochemical Relapse, and Side Effects of Hormonal Treatment: Report of the Advanced Prostate Cancer Consensus Conference 2022. Eur Urol. 2023 03; 83(3):267-293. View in: Pubmed

      • The NOGO receptor NgR2, a novel aVß3 integrin effector, induces neuroendocrine differentiation in prostate cancer. Sci Rep. 2022 11 07; 12(1):18879. View in: Pubmed

      • DLL3 as an Emerging Target for the Treatment of Neuroendocrine Neoplasms. Oncologist. 2022 11 03; 27(11):940-951. View in: Pubmed

      • Response to MEK Inhibitor Therapy in MAP2K1 (MEK1) K57N Non-Small-Cell Lung Cancer and Genomic Landscape of MAP2K1 Mutations in Non-Small-Cell Lung Cancer. JCO Precis Oncol. 2022 11; 6:e2200382. View in: Pubmed

      • A clinical-grade liquid biomarker detects neuroendocrine differentiation in prostate cancer. J Clin Invest. 2022 11 01; 132(21). View in: Pubmed

      • CHD1 Promotes Sensitivity to Aurora Kinase Inhibitors by Suppressing Interaction of AURKA with Its Coactivator TPX2. Cancer Res. 2022 09 02; 82(17):3088-3101. View in: Pubmed

      • Moving Precision Oncology for Advanced Prostate Cancer from Theory to Practice. Eur Urol Focus. 2023 01; 9(1):110-113. View in: Pubmed

      • Future directions for precision oncology in prostate cancer. Prostate. 2022 08; 82 Suppl 1:S86-S96. View in: Pubmed

      • Predictive Biomarkers of Overall Survival in Patients with Metastatic Renal Cell Carcinoma Treated with IFNa ± Bevacizumab: Results from CALGB 90206 (Alliance). Clin Cancer Res. 2022 07 01; 28(13):2771-2778. View in: Pubmed

      • Chromatin profiles classify castration-resistant prostate cancers suggesting therapeutic targets. Science. 2022 05 27; 376(6596):eabe1505. View in: Pubmed

      • Allele-informed copy number evaluation of plasma DNA samples from metastatic prostate cancer patients: the PCF_SELECT consortium assay. NAR Cancer. 2022 Jun; 4(2):zcac016. View in: Pubmed

      • Recent clinical trial data of androgen receptor inhibitors in patients with nonmetastatic castration-resistant prostate cancer. Clin Adv Hematol Oncol. 2022 05; 20 Suppl 9(5):2-8. View in: Pubmed

      • Factors that guide selection among androgen receptor inhibitors in patients with nonmetastatic castration-resistant prostate cancer. Clin Adv Hematol Oncol. 2022 May; 20 Suppl 9(5):1-20. View in: Pubmed

      • Editorial: Metastatic prostate cancer: a wealth of data to put into practice. Curr Opin Urol. 2022 05 01; 32(3):267-268. View in: Pubmed

      • Management of Patients with Advanced Prostate Cancer: Report from the Advanced Prostate Cancer Consensus Conference 2021. Eur Urol. 2022 07; 82(1):115-141. View in: Pubmed

      • Corrigendum to "What Experts Think About Prostate Cancer Management During the COVID-19 Pandemic: Report from the Advanced Prostate Cancer Consensus Conference 2021" [Eur Urol 82(1):6-11]. Eur Urol. 2022 Jul; 82(1):e18-e19. View in: Pubmed

      • The genomic landscape of metastatic clear cell renal cell carcinoma after systemic therapy. Mol Oncol. 2022 06; 16(12):2384-2395. View in: Pubmed

      • Comparative genomics of primary prostate cancer and paired metastases: insights from 12 molecular case studies. J Pathol. 2022 07; 257(3):274-284. View in: Pubmed

      • Detecting Neuroendocrine Prostate Cancer Through Tissue-Informed Cell-Free DNA Methylation Analysis. Clin Cancer Res. 2022 Mar 01; 28(5):928-938. View in: Pubmed

      • What Experts Think About Prostate Cancer Management During the COVID-19 Pandemic: Report from the Advanced Prostate Cancer Consensus Conference 2021. Eur Urol. 2022 07; 82(1):6-11. View in: Pubmed

      • Identification of alternative protein targets of glutamate-ureido-lysine associated with PSMA tracer uptake in prostate cancer cells. Proc Natl Acad Sci U S A. 2022 01 25; 119(4). View in: Pubmed

      • Isn't Androgen Deprivation Enough? Optimal Treatment for Newly Diagnosed Metastatic Prostate Cancer. J Clin Oncol. 2022 03 10; 40(8):818-824. View in: Pubmed

      • Germline BRCA2 mutation in a case of aggressive prostate cancer accompanied by spinal bulbar muscular atrophy. Asian J Androl. 2022 Jan-Feb; 24(1):116-118. View in: Pubmed

      • Tribbles 2 pseudokinase confers enzalutamide resistance in prostate cancer by promoting lineage plasticity. J Biol Chem. 2022 02; 298(2):101556. View in: Pubmed

      • The long noncoding RNA H19 regulates tumor plasticity in neuroendocrine prostate cancer. Nat Commun. 2021 12 21; 12(1):7349. View in: Pubmed

      • Towards Biologically Driven Decision-making in Metastatic Hormone-sensitive Prostate Cancer. Eur Urol Oncol. 2021 12; 4(6):924-926. View in: Pubmed

      • Extracellular Matrix in Synthetic Hydrogel-Based Prostate Cancer Organoids Regulate Therapeutic Response to EZH2 and DRD2 Inhibitors. Adv Mater. 2022 Jan; 34(2):e2100096. View in: Pubmed

      • Leveraging Real World Genomic Data to Advance Prostate Cancer Precision Oncology. Eur Urol. 2022 01; 81(1):48-49. View in: Pubmed

      • Opposing transcriptional programs of KLF5 and AR emerge during therapy for advanced prostate cancer. Nat Commun. 2021 11 04; 12(1):6377. View in: Pubmed

      • Plasma tumor DNA is associated with increased risk of venous thromboembolism in metastatic castration-resistant cancer patients. Int J Cancer. 2022 04 01; 150(7):1166-1173. View in: Pubmed

      • Subtype heterogeneity and epigenetic convergence in neuroendocrine prostate cancer. Nat Commun. 2021 10 01; 12(1):5775. View in: Pubmed

      • Author Correction: Circulating tumor cell heterogeneity in neuroendocrine prostate cancer by single cell copy number analysis. NPJ Precis Oncol. 2021 Sep 13; 5(1):84. View in: Pubmed

      • An androgen receptor switch underlies lineage infidelity in treatment-resistant prostate cancer. Nat Cell Biol. 2021 09; 23(9):1023-1034. View in: Pubmed

      • Novel genomic signature predictive of response to immune checkpoint blockade: A pan-cancer analysis from project Genomics Evidence Neo-plasia Information Exchange (GENIE). Cancer Genet. 2021 11; 258-259:61-68. View in: Pubmed

      • Circulating tumor cell heterogeneity in neuroendocrine prostate cancer by single cell copy number analysis. NPJ Precis Oncol. 2021 Aug 12; 5(1):76. View in: Pubmed

      • Prostate cancer. Lancet. 2021 09 18; 398(10305):1075-1090. View in: Pubmed

      • A phase I/II study of rovalpituzumab tesirine in delta-like 3-expressing advanced solid tumors. NPJ Precis Oncol. 2021 Aug 05; 5(1):74. View in: Pubmed

      • Therapy considerations in neuroendocrine prostate cancer: what next? Endocr Relat Cancer. 2021 07 15; 28(8):T67-T78. View in: Pubmed

      • Combined Longitudinal Clinical and Autopsy Phenomic Assessment in Lethal Metastatic Prostate Cancer: Recommendations for Advancing Precision Medicine. Eur Urol Open Sci. 2021 Aug; 30:47-62. View in: Pubmed

      • Epigenetics in prostate cancer: clinical implications. Transl Androl Urol. 2021 Jul; 10(7):3104-3116. View in: Pubmed

      • Androgen receptor variant shows heterogeneous expression in prostate cancer according to differentiation stage. Commun Biol. 2021 06 24; 4(1):785. View in: Pubmed

      • The treatment landscape of metastatic prostate cancer. Cancer Lett. 2021 10 28; 519:20-29. View in: Pubmed

      • BET Bromodomain Inhibition Blocks an AR-Repressed, E2F1-Activated Treatment-Emergent Neuroendocrine Prostate Cancer Lineage Plasticity Program. Clin Cancer Res. 2021 09 01; 27(17):4923-4936. View in: Pubmed

      • Temporal evolution of cellular heterogeneity during the progression to advanced AR-negative prostate cancer. Nat Commun. 2021 06 07; 12(1):3372. View in: Pubmed

      • Targeting the epichaperome as an effective precision medicine approach in a novel PML-SYK fusion acute myeloid leukemia. NPJ Precis Oncol. 2021 May 26; 5(1):44. View in: Pubmed

      • Reprogramming of the FOXA1 cistrome in treatment-emergent neuroendocrine prostate cancer. Nat Commun. 2021 03 30; 12(1):1979. View in: Pubmed

      • Transcriptional mediators of treatment resistance in lethal prostate cancer. Nat Med. 2021 03; 27(3):426-433. View in: Pubmed

      • Activated ALK Cooperates with N-Myc via Wnt/ß-Catenin Signaling to Induce Neuroendocrine Prostate Cancer. Cancer Res. 2021 04 15; 81(8):2157-2170. View in: Pubmed

      • Clinical considerations for the management of androgen indifferent prostate cancer. Prostate Cancer Prostatic Dis. 2021 09; 24(3):623-637. View in: Pubmed

      • Clinical and Biological Features of Neuroendocrine Prostate Cancer. Curr Oncol Rep. 2021 01 12; 23(2):15. View in: Pubmed

      • Prostate Cancer Foundation Hormone-Sensitive Prostate Cancer Biomarker Working Group Meeting Summary. Urology. 2021 09; 155:165-171. View in: Pubmed

      • Common germline-somatic variant interactions in advanced urothelial cancer. Nat Commun. 2020 12 03; 11(1):6195. View in: Pubmed

      • Accelerating precision medicine in metastatic prostate cancer. Nat Cancer. 2020 11; 1(11):1041-1053. View in: Pubmed

      • Integration of whole-exome and anchored PCR-based next generation sequencing significantly increases detection of actionable alterations in precision oncology. Transl Oncol. 2021 Jan; 14(1):100944. View in: Pubmed

      • Role of specialized composition of SWI/SNF complexes in prostate cancer lineage plasticity. Nat Commun. 2020 11 03; 11(1):5549. View in: Pubmed

      • Taxane-induced Attenuation of the CXCR2/BCL-2 Axis Sensitizes Prostate Cancer to Platinum-based Treatment. Eur Urol. 2021 06; 79(6):722-733. View in: Pubmed

      • Activity of Platinum-Based Chemotherapy in Patients With Advanced Prostate Cancer With and Without DNA Repair Gene Aberrations. JAMA Netw Open. 2020 10 01; 3(10):e2021692. View in: Pubmed

      • Cancer and Leukemia Group B 90203 (Alliance): Radical Prostatectomy With or Without Neoadjuvant Chemohormonal Therapy in Localized, High-Risk Prostate Cancer. J Clin Oncol. 2020 09 10; 38(26):3042-3050. View in: Pubmed

      • Implementation of Germline Testing for Prostate Cancer: Philadelphia Prostate Cancer Consensus Conference 2019. J Clin Oncol. 2020 08 20; 38(24):2798-2811. View in: Pubmed

      • Small extracellular vesicles modulated by aVß3 integrin induce neuroendocrine differentiation in recipient cancer cells. J Extracell Vesicles. 2020 May 24; 9(1):1761072. View in: Pubmed

      • ABEMUS: platform-specific and data-informed detection of somatic SNVs in cfDNA. Bioinformatics. 2020 05 01; 36(9):2665-2674. View in: Pubmed

      • PIM protein kinases regulate the level of the long noncoding RNA H19 to control stem cell gene transcription and modulate tumor growth. Mol Oncol. 2020 05; 14(5):974-990. View in: Pubmed

      • Circulating tumor DNA profile recognizes transformation to castration-resistant neuroendocrine prostate cancer. J Clin Invest. 2020 04 01; 130(4):1653-1668. View in: Pubmed

      • SLFN11 Expression in Advanced Prostate Cancer and Response to Platinum-based Chemotherapy. Mol Cancer Ther. 2020 05; 19(5):1157-1164. View in: Pubmed

      • Docetaxel for Early Prostate Cancer: What Have We Learned? Eur Urol. 2020 05; 77(5):573-575. View in: Pubmed

      • Molecular Biomarkers in Localized Prostate Cancer: ASCO Guideline Summary. JCO Oncol Pract. 2020 06; 16(6):340-343. View in: Pubmed

      • Management of Patients with Advanced Prostate Cancer: Report of the Advanced Prostate Cancer Consensus Conference 2019. Eur Urol. 2020 04; 77(4):508-547. View in: Pubmed

      • Androgen deprivation upregulates SPINK1 expression and potentiates cellular plasticity in prostate cancer. Nat Commun. 2020 01 20; 11(1):384. View in: Pubmed

      • Genomic and clinical characterization of stromal infiltration markers in prostate cancer. Cancer. 2020 04 01; 126(7):1407-1412. View in: Pubmed

      • Molecular Biomarkers in Localized Prostate Cancer: ASCO Guideline. J Clin Oncol. 2020 05 01; 38(13):1474-1494. View in: Pubmed

      • Management of patients with advanced prostate cancer: recommendations of the St Gallen Advanced Prostate Cancer Consensus Conference (APCCC) 2015. Ann Oncol. 2019 12; 30(12):e3. View in: Pubmed

      • Organotypic tumor slice cultures provide a versatile platform for immuno-oncology and drug discovery. Oncoimmunology. 2019; 8(12):e1670019. View in: Pubmed

      • Towards precision oncology in advanced prostate cancer. Nat Rev Urol. 2019 11; 16(11):645-654. View in: Pubmed

      • The Balancing Act: Assessing Treatment Burden Versus Treatment Benefit with Evolving Metastatic Hormone-sensitive Prostate Cancer Data. Eur Urol. 2019 12; 76(6):729-731. View in: Pubmed

      • Integrative Molecular Analysis of Patients With Advanced and Metastatic Cancer. JCO Precis Oncol. 2019; 3. View in: Pubmed

      • Clinical features of neuroendocrine prostate cancer. Eur J Cancer. 2019 11; 121:7-18. View in: Pubmed

      • PARP Inhibition Suppresses GR-MYCN-CDK5-RB1-E2F1 Signaling and Neuroendocrine Differentiation in Castration-Resistant Prostate Cancer. Clin Cancer Res. 2019 11 15; 25(22):6839-6851. View in: Pubmed

      • Proteomic and genomic signatures of repeat instability in cancer and adjacent normal tissues. Proc Natl Acad Sci U S A. 2019 08 20; 116(34):16987-16996. View in: Pubmed

      • Cancer-Specific Thresholds Adjust for Whole Exome Sequencing-based Tumor Mutational Burden Distribution. JCO Precis Oncol. 2019; 3. View in: Pubmed

      • The Role of Lineage Plasticity in Prostate Cancer Therapy Resistance. Clin Cancer Res. 2019 12 01; 25(23):6916-6924. View in: Pubmed

      • Upper tract urothelial carcinoma has a luminal-papillary T-cell depleted contexture and activated FGFR3 signaling. Nat Commun. 2019 07 05; 10(1):2977. View in: Pubmed

      • N-Myc-mediated epigenetic reprogramming drives lineage plasticity in advanced prostate cancer. J Clin Invest. 2019 07 01; 129(9):3924-3940. View in: Pubmed

      • Publisher Correction: The long tail of oncogenic drivers in prostate cancer. Nat Genet. 2019 Jul; 51(7):1194. View in: Pubmed

      • Erratum: CRIPTO overexpression promotes mesenchymal differentiation in prostate carcinoma cells through parallel regulation of AKT and FGFR activities. Oncotarget. 2019 06 25; 10(41):4247-4248. View in: Pubmed

      • Transcriptomic and Clinical Characterization of Neuropeptide Y Expression in Localized and Metastatic Prostate Cancer: Identification of Novel Prostate Cancer Subtype with Clinical Implications. Eur Urol Oncol. 2019 07; 2(4):405-412. View in: Pubmed

      • Retinoblastoma Loss in Cancer: Casting a Wider Net. Clin Cancer Res. 2019 07 15; 25(14):4199-4201. View in: Pubmed

      • CHD1 Loss Alters AR Binding at Lineage-Specific Enhancers and Modulates Distinct Transcriptional Programs to Drive Prostate Tumorigenesis. Cancer Cell. 2019 May 13; 35(5):817-819. View in: Pubmed

      • Genomic correlates of clinical outcome in advanced prostate cancer. Proc Natl Acad Sci U S A. 2019 06 04; 116(23):11428-11436. View in: Pubmed

      • Ultrasensitive detection of cancer biomarkers by nickel-based isolation of polydisperse extracellular vesicles from blood. EBioMedicine. 2019 May; 43:114-126. View in: Pubmed

      • Phase 1/2 study of fractionated dose lutetium-177-labeled anti-prostate-specific membrane antigen monoclonal antibody J591 (177 Lu-J591) for metastatic castration-resistant prostate cancer. Cancer. 2019 08 01; 125(15):2561-2569. View in: Pubmed

      • Exceptional Response to Pembrolizumab in a Patient With Castration-Resistant Prostate Cancer With Pancytopenia From Myelophthisis. J Oncol Pract. 2019 06; 15(6):343-345. View in: Pubmed

      • CHD1 Loss Alters AR Binding at Lineage-Specific Enhancers and Modulates Distinct Transcriptional Programs to Drive Prostate Tumorigenesis. Cancer Cell. 2019 04 15; 35(4):603-617.e8. View in: Pubmed

      • Delta-like protein 3 expression and therapeutic targeting in neuroendocrine prostate cancer. Sci Transl Med. 2019 03 20; 11(484). View in: Pubmed

      • Increased Serine and One-Carbon Pathway Metabolism by PKC?/? Deficiency Promotes Neuroendocrine Prostate Cancer. Cancer Cell. 2019 03 18; 35(3):385-400.e9. View in: Pubmed

      • Identification of a therapeutic target using molecular sequencing for treatment of recurrent uterine serous adenocarcinoma. Gynecol Oncol Rep. 2019 May; 28:54-57. View in: Pubmed

      • Biological Evolution of Castration-resistant Prostate Cancer. Eur Urol Focus. 2019 03; 5(2):147-154. View in: Pubmed

      • Neuroendocrine Differentiation in Prostate Cancer: Emerging Biology, Models, and Therapies. Cold Spring Harb Perspect Med. 2019 02 01; 9(2). View in: Pubmed

      • The application of precision medicine in diagnosing familial Mediterranean fever. Leuk Lymphoma. 2019 08; 60(8):2091-2093. View in: Pubmed

      • ONECUT2 is a driver of neuroendocrine prostate cancer. Nat Commun. 2019 01 17; 10(1):278. View in: Pubmed

      • Low Tristetraprolin Expression Is Associated with Lethal Prostate Cancer. Cancer Epidemiol Biomarkers Prev. 2019 03; 28(3):584-590. View in: Pubmed

      • Immunogenomic analyses associate immunological alterations with mismatch repair defects in prostate cancer. J Clin Invest. 2018 11 01; 128(11):5185. View in: Pubmed

      • Publisher Correction: Suppression of insulin feedback enhances the efficacy of PI3K inhibitors. Nature. 2018 11; 563(7731):E24. View in: Pubmed

      • Plasma androgen receptor and serum chromogranin A in advanced prostate cancer. Sci Rep. 2018 10 18; 8(1):15442. View in: Pubmed

      • CD38 is methylated in prostate cancer and regulates extracellular NAD. Cancer Metab. 2018; 6:13. View in: Pubmed

      • A Phase II Trial of the Aurora Kinase A Inhibitor Alisertib for Patients with Castration-resistant and Neuroendocrine Prostate Cancer: Efficacy and Biomarkers. Clin Cancer Res. 2019 01 01; 25(1):43-51. View in: Pubmed

      • The Role of Next-Generation Sequencing in Precision Medicine: A Review of Outcomes in Oncology. J Pers Med. 2018 Sep 17; 8(3). View in: Pubmed

      • Linking prostate cancer cell AR heterogeneity to distinct castration and enzalutamide responses. Nat Commun. 2018 09 06; 9(1):3600. View in: Pubmed

      • Immunogenomic analyses associate immunological alterations with mismatch repair defects in prostate cancer. J Clin Invest. 2018 10 01; 128(10):4441-4453. View in: Pubmed

      • Biallelic tumour suppressor loss and DNA repair defects in de novo small-cell prostate carcinoma. J Pathol. 2018 10; 246(2):244-253. View in: Pubmed

      • Evolving Intersection Between Inherited Cancer Genetics and Therapeutic Clinical Trials in Prostate Cancer: A White Paper From the Germline Genetics Working Group of the Prostate Cancer Clinical Trials Consortium. JCO Precis Oncol. 2018; 2018. View in: Pubmed

      • Clinical and Genomic Characterization of Treatment-Emergent Small-Cell Neuroendocrine Prostate Cancer: A Multi-institutional Prospective Study. J Clin Oncol. 2018 08 20; 36(24):2492-2503. View in: Pubmed

      • Suppression of insulin feedback enhances the efficacy of PI3K inhibitors. Nature. 2018 08; 560(7719):499-503. View in: Pubmed

      • BRCA2-Associated Prostate Cancer in a Patient With Spinal and Bulbar Muscular Atrophy. JCO Precis Oncol. 2018; 2. View in: Pubmed

      • Patient derived organoids to model rare prostate cancer phenotypes. Nat Commun. 2018 06 19; 9(1):2404. View in: Pubmed

      • The long noncoding RNA landscape of neuroendocrine prostate cancer and its clinical implications. Gigascience. 2018 06 01; 7(6). View in: Pubmed

      • CATCH-KB: Establishing a Pharmacogenomics Variant Repository for Chemotherapy-Induced Cardiotoxicity. AMIA Jt Summits Transl Sci Proc. 2018; 2017:168-177. View in: Pubmed

      • The long tail of oncogenic drivers in prostate cancer. Nat Genet. 2018 05; 50(5):645-651. View in: Pubmed

      • Cellular plasticity and the neuroendocrine phenotype in prostate cancer. Nat Rev Urol. 2018 05; 15(5):271-286. View in: Pubmed

      • Clinical Outcome of Prostate Cancer Patients with Germline DNA Repair Mutations: Retrospective Analysis from an International Study. Eur Urol. 2018 05; 73(5):687-693. View in: Pubmed

      • Naming disease states for clinical utility in prostate cancer: a rose by any other name might not smell as sweet. Ann Oncol. 2018 01 01; 29(1):23-25. View in: Pubmed

      • Bone biopsy protocol for advanced prostate cancer in the era of precision medicine. Cancer. 2018 03 01; 124(5):1008-1015. View in: Pubmed

      • Aberrant Activation of a Gastrointestinal Transcriptional Circuit in Prostate Cancer Mediates Castration Resistance. Cancer Cell. 2017 Dec 11; 32(6):792-806.e7. View in: Pubmed

      • Rapid autopsy of a patient with recurrent anaplastic ependymoma. Palliat Support Care. 2018 04; 16(2):238-242. View in: Pubmed

      • Impact of Therapy on Genomics and Transcriptomics in High-Risk Prostate Cancer Treated with Neoadjuvant Docetaxel and Androgen Deprivation Therapy. Clin Cancer Res. 2017 Nov 15; 23(22):6802-6811. View in: Pubmed

      • Management of Patients with Advanced Prostate Cancer: The Report of the Advanced Prostate Cancer Consensus Conference APCCC 2017. Eur Urol. 2018 02; 73(2):178-211. View in: Pubmed

      • Next-Generation Rapid Autopsies Enable Tumor Evolution Tracking and Generation of Preclinical Models. JCO Precis Oncol. 2017; 2017. View in: Pubmed

      • Biology and evolution of poorly differentiated neuroendocrine tumors. Nat Med. 2017 Jun 06; 23(6):1-10. View in: Pubmed

      • A germline FANCA alteration that is associated with increased sensitivity to DNA damaging agents. Cold Spring Harb Mol Case Stud. 2017 Sep; 3(5). View in: Pubmed

      • Erratum to: Unraveling the clonal hierarchy of somatic genomic aberrations. Genome Biol. 2017 05 02; 18(1):80. View in: Pubmed

      • Transplantation of engineered organoids enables rapid generation of metastatic mouse models of colorectal cancer. Nat Biotechnol. 2017 06; 35(6):577-582. View in: Pubmed

      • Emerging Variants of Castration-Resistant Prostate Cancer. Curr Oncol Rep. 2017 May; 19(5):32. View in: Pubmed

      • On-site Cytology for Development of Patient-Derived Three-dimensional Organoid Cultures - A Pilot Study. Anticancer Res. 2017 04; 37(4):1569-1573. View in: Pubmed

      • Personalized In Vitro and In Vivo Cancer Models to Guide Precision Medicine. Cancer Discov. 2017 05; 7(5):462-477. View in: Pubmed

      • The clone wars. Sci Transl Med. 2017 02 15; 9(377). View in: Pubmed

      • SOX2 promotes lineage plasticity and antiandrogen resistance in TP53- and RB1-deficient prostate cancer. Science. 2017 01 06; 355(6320):84-88. View in: Pubmed

      • Unleashing the wrath of Ras. Sci Transl Med. 2017 01 04; 9(371). View in: Pubmed

      • Prostate cancer in 2016: Improved outcomes and precision medicine come within reach. Nat Rev Urol. 2017 Feb; 14(2):71-72. View in: Pubmed

      • Personalizing Therapy for Metastatic Prostate Cancer: The Role of Solid and Liquid Tumor Biopsies. Am Soc Clin Oncol Educ Book. 2017; 37:358-369. View in: Pubmed

      • Synthetic lethality and beyond. Sci Transl Med. 2016 11 16; 8(365):365ec182. View in: Pubmed

      • The Master Neural Transcription Factor BRN2 Is an Androgen Receptor-Suppressed Driver of Neuroendocrine Differentiation in Prostate Cancer. Cancer Discov. 2017 01; 7(1):54-71. View in: Pubmed

      • Clonal evolution of chemotherapy-resistant urothelial carcinoma. Nat Genet. 2016 12; 48(12):1490-1499. View in: Pubmed

      • N-Myc Induces an EZH2-Mediated Transcriptional Program Driving Neuroendocrine Prostate Cancer. Cancer Cell. 2016 10 10; 30(4):563-577. View in: Pubmed

      • Development and validation of a whole-exome sequencing test for simultaneous detection of point mutations, indels and copy-number alterations for precision cancer care. NPJ Genom Med. 2016; 1. View in: Pubmed

      • Inherited DNA-Repair Gene Mutations in Men with Metastatic Prostate Cancer. N Engl J Med. 2016 Aug 04; 375(5):443-53. View in: Pubmed

      • Update on the biology and management of neuroendocrine prostate cancer. Clin Adv Hematol Oncol. 2016 Jul; 14(7):513-5. View in: Pubmed

      • SRRM4 Drives Neuroendocrine Transdifferentiation of Prostate Adenocarcinoma Under Androgen Receptor Pathway Inhibition. Eur Urol. 2017 01; 71(1):68-78. View in: Pubmed

      • Management of patients with advanced prostate cancer: recommendations of the St Gallen Advanced Prostate Cancer Consensus Conference (APCCC) 2015. Ann Oncol. 2019 12; 30(12):e3. View in: Pubmed

      • PO-43 - Differential coagulation factor expression in neuroendocrine prostate cancer (PC), metastatic castrate-resistant PC, and localized prostatic adenocarcinoma. Thromb Res. 2016 Apr; 140 Suppl 1:S192. View in: Pubmed

      • Divergent clonal evolution of castration-resistant neuroendocrine prostate cancer. Nat Med. 2016 Mar; 22(3):298-305. View in: Pubmed

      • Emerging Molecular Biomarkers in Advanced Prostate Cancer: Translation to the Clinic. Am Soc Clin Oncol Educ Book. 2016; 35:131-41. View in: Pubmed

      • The Initial Detection and Partial Characterization of Circulating Tumor Cells in Neuroendocrine Prostate Cancer. Clin Cancer Res. 2016 Mar 15; 22(6):1510-9. View in: Pubmed

      • An emerging role for cytopathology in precision oncology. Cancer Cytopathol. 2016 Mar; 124(3):167-73. View in: Pubmed

      • The Placental Gene PEG10 Promotes Progression of Neuroendocrine Prostate Cancer. Cell Rep. 2015 Aug 11; 12(6):922-36. View in: Pubmed

      • Prostate cancer: Intrapatient heterogeneity in prostate cancer. Nat Rev Urol. 2015 Aug; 12(8):430-1. View in: Pubmed

      • Integrative Clinical Genomics of Advanced Prostate Cancer. Cell. 2015 Jul 16; 162(2):454. View in: Pubmed

      • Whole-Exome Sequencing of Metastatic Cancer and Biomarkers of Treatment Response. JAMA Oncol. 2015 Jul; 1(4):466-74. View in: Pubmed

      • Management of patients with advanced prostate cancer: recommendations of the St Gallen Advanced Prostate Cancer Consensus Conference (APCCC) 2015. Ann Oncol. 2015 Aug; 26(8):1589-604. View in: Pubmed

      • Integrative clinical genomics of advanced prostate cancer. Cell. 2015 May 21; 161(5):1215-1228. View in: Pubmed

      • CRIPTO overexpression promotes mesenchymal differentiation in prostate carcinoma cells through parallel regulation of AKT and FGFR activities. Oncotarget. 2015 May 20; 6(14):11994-2008. View in: Pubmed

      • Prioritizing precision medicine for prostate cancer. Ann Oncol. 2015 Jun; 26(6):1041-1042. View in: Pubmed

      • The spectrum of neuroendocrine tumors: histologic classification, unique features and areas of overlap. Am Soc Clin Oncol Educ Book. 2015; 92-103. View in: Pubmed

      • ERG induces taxane resistance in castration-resistant prostate cancer. Nat Commun. 2014 Nov 25; 5:5548. View in: Pubmed

      • The oestrogen receptor alpha-regulated lncRNA NEAT1 is a critical modulator of prostate cancer. Nat Commun. 2014 Nov 21; 5:5383. View in: Pubmed

      • Organoid cultures derived from patients with advanced prostate cancer. Cell. 2014 Sep 25; 159(1):176-187. View in: Pubmed

      • Unraveling the clonal hierarchy of somatic genomic aberrations. Genome Biol. 2014 Aug 26; 15(8):439. View in: Pubmed

      • Exploring the role of anti-angiogenic therapies in prostate cancer: results from the phase 3 trial of sunitinib. Asian J Androl. 2014 Jul-Aug; 16(4):568-9. View in: Pubmed

      • Prostate cancer with Paneth cell-like neuroendocrine differentiation has recognizable histomorphology and harbors AURKA gene amplification. Hum Pathol. 2014 Oct; 45(10):2136-43. View in: Pubmed

      • Proposed morphologic classification of prostate cancer with neuroendocrine differentiation. Am J Surg Pathol. 2014 Jun; 38(6):756-67. View in: Pubmed

      • Aggressive variants of castration-resistant prostate cancer. Clin Cancer Res. 2014 Jun 01; 20(11):2846-50. View in: Pubmed

      • The many faces of neuroendocrine differentiation in prostate cancer progression. Front Oncol. 2014; 4:60. View in: Pubmed

      • The N-myc Oncogene: Maximizing its Targets, Regulation, and Therapeutic Potential. Mol Cancer Res. 2014 Jun; 12(6):815-22. View in: Pubmed

      • High fidelity patient-derived xenografts for accelerating prostate cancer discovery and drug development. Cancer Res. 2014 Feb 15; 74(4):1272-83. View in: Pubmed

      • Development and validation of a clinical cancer genomic profiling test based on massively parallel DNA sequencing. Nat Biotechnol. 2013 Nov; 31(11):1023-31. View in: Pubmed

      • Cross modulation between the androgen receptor axis and protocadherin-PC in mediating neuroendocrine transdifferentiation and therapeutic resistance of prostate cancer. Neoplasia. 2013 Jul; 15(7):761-72. View in: Pubmed

      • Punctuated evolution of prostate cancer genomes. Cell. 2013 Apr 25; 153(3):666-77. View in: Pubmed

      • Epigenomic alterations in localized and advanced prostate cancer. Neoplasia. 2013 Apr; 15(4):373-83. View in: Pubmed

      • DNA mismatch repair in prostate cancer. J Clin Oncol. 2013 May 10; 31(14):1782-4. View in: Pubmed

      • Concurrent AURKA and MYCN gene amplifications are harbingers of lethal treatment-related neuroendocrine prostate cancer. Neoplasia. 2013 Jan; 15(1):1-10. View in: Pubmed

      • New strategies in prostate cancer: translating genomics into the clinic. Clin Cancer Res. 2013 Feb 01; 19(3):517-23. View in: Pubmed

      • Epigenetic repression of miR-31 disrupts androgen receptor homeostasis and contributes to prostate cancer progression. Cancer Res. 2013 Feb 01; 73(3):1232-44. View in: Pubmed

      • Challenges in recognizing treatment-related neuroendocrine prostate cancer. J Clin Oncol. 2012 Dec 20; 30(36):e386-9. View in: Pubmed

      • Targeted next-generation sequencing of advanced prostate cancer identifies potential therapeutic targets and disease heterogeneity. Eur Urol. 2013 May; 63(5):920-6. View in: Pubmed

      • From sequence to molecular pathology, and a mechanism driving the neuroendocrine phenotype in prostate cancer. J Pathol. 2012 Jul; 227(3):286-97. View in: Pubmed

      • Editorial comment. J Urol. 2012 Jul; 188(1):108-9. View in: Pubmed

      • Identification of functionally active, low frequency copy number variants at 15q21.3 and 12q21.31 associated with prostate cancer risk. Proc Natl Acad Sci U S A. 2012 Apr 24; 109(17):6686-91. View in: Pubmed

      • Next generation sequencing of prostate cancer from a patient identifies a deficiency of methylthioadenosine phosphorylase, an exploitable tumor target. Mol Cancer Ther. 2012 Mar; 11(3):775-83. View in: Pubmed

      • Molecular characterization of neuroendocrine prostate cancer and identification of new drug targets. Cancer Discov. 2011 Nov; 1(6):487-95. View in: Pubmed

      • Novel therapeutics for the management of castration-resistant prostate cancer (CRPC). BJU Int. 2012 Apr; 109(7):968-85. View in: Pubmed

      • Abiraterone plus prednisone improves survival in metastatic castration-resistant prostate cancer. Asian J Androl. 2011 Nov; 13(6):785-6. View in: Pubmed

      • New therapies for castration-resistant prostate cancer: efficacy and safety. Eur Urol. 2011 Aug; 60(2):279-90. View in: Pubmed

      • Primary squamous cell carcinoma of the urinary bladder presenting as peritoneal carcinomatosis. Adv Urol. 2010; 179250. View in: Pubmed

      • Anti-prostate-specific membrane antigen-based radioimmunotherapy for prostate cancer. Cancer. 2010 Feb 15; 116(4 Suppl):1075-83. View in: Pubmed

      Locations

      Location Avtar

      Dana-Farber Cancer Institute

      450 Brookline Avenue Boston, MA 02215
      Get Directions

      Dana-Farber Cancer Institute

      Location Avtar

      Dana-Farber Cancer Institute

      450 Brookline Avenue Boston, MA 02215
      Get Direction
      42.3374, -71.1082

      Ratings and Comments

      Himisha Beltran, MD

      About Our Ratings

      Physician Star Rating Comment Block